Please login to the form below
squamous cell cancer
This page shows the latest squamous cell cancer news and features for those working in and with pharma, biotech and healthcare.
Bluebird and Celgene BCMA CAR-T kicks off ASCO
Bluebird and Celgene BCMA CAR-T kicks off ASCO. Will be reporting updated phase I trial data for bb2121in patients with bone marrow cancer. ... option for patients with metastatic squamous non-small cell lung cancer (NSCLC) - regardless of PD-L1
Latest news
-
Daily Brief: AstraZeneca's new San Fran hoKeytruda triumphs again, Novo branches out
Topline data from its Keynote 407 study of the drug as a first-line treatment for metastatic squamous non-small cell lung cancer (sNSCLC), met the dual primary endpoints of improved ... Previously untreated patients with the squamous NSCLC, represent
-
Roche eyes September FDA verdict for triple NSCLC therapy
The FDA has started a six-month review of Roche’s Tecentriq, Avastin and chemotherapy in first-line non-small cell lung cancer, setting up a possible approval by 5 September. ... Roche is pairing Tecentriq and Avastin in multiple cancer indications,
-
New data could put Roche’s Tecentriq first in squamous lung cancer
small cell lung cancer (NSCLC) reduced the risk of disease worsening or death compared to chemotherapy alone. ... Squamous non-small cell lung cancer is difficult to treat and there have been limited new treatment options over the last few decades,
-
Data backs up Roche’s Tecentriq/Avastin combo in lung cancer
Giving Tecentriq (atezolizumab) and Avastin (bevacizumab) on top of chemotherapy to previously-untreated patients with advanced non-squamous non-small-cell lung cancer (NSCLC) resulted in a 38% reduction in PFS ... group of people with advanced
-
Merck pulls Keytruda filing in Europe, despite US approval
EU regulators don’t seem to be as comfortable with Merck &Co’s data on Keytruda as a first-line treatment for non-squamous non-small cell lung cancer (NSCLC) as ... The decision shows that EU regulators are not happy to approve new cancer drugs based
More from news
Approximately 0 fully matching, plus 51 partially matching documents found.
Latest appointments
-
BIND Therapeutics appoints Andrew Hirsch as permanent CEO
Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Business Unit Head, Medical Communications, London
-
Excellent package
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Client Services Director - Med Comms
-
Great salary and bebefits
Subscribe to our email news alerts
- Moving annual total (MAT)
- Brexit rebels win vote on European Medicines Agency alignment
- MaxCyte gets green light for solid tumour cell therapy
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- NHS England to Vertex: come clean on Orkambi offer
- AstraZeneca joins Merck in Brexit stockpiling effort
- Random42 win Creativity International Award for Scientific Animation
- Merck & Co joins big pharma pricing pledge – but sceptics unconvinced
- Aurora partners with PIPHealth and taps into patient panels
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
PMHub
Ashfield
Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
